Cure My Disease

Don't miss your cure!

 Log in / Sign up

Weight-Loss drugs may offer early liver protection, study suggests

NCT ID NCT07701005

Knowledge-focused Sponsor: Goztepe Prof Dr Suleyman Yalcın City Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 14, 2026 · Last updated Jul 16, 2026 · Updated 2 times

Summary

This study looks at whether two popular weight-loss medications, semaglutide and tirzepatide, can improve early signs of liver damage in people with overweight or obesity. Researchers measured changes in liver health markers after at least 12 weeks of treatment in 154 adults. The goal is to see if these drugs might help prevent fatty liver disease and related metabolic problems.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
semaglutide or tirzepatide, injected weekly
What this could lead to
If successful, this study could show that these medications improve liver health in people with overweight or obesity, potentially reducing the risk of liver disease.
What could go wrong
This is a small, retrospective study from a single center, so results may not apply to everyone. It only looks at early changes, not long-term outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

154 people

The number who actually took part.

Started

Jan 2024

Finished

Apr 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults with overweight or obesity at increased metabolic risk for MASLD, treated with subcutaneous semaglutide or tirzepatide for at least 12 weeks at a single tertiary-care internal medicine clinic in Turkey; both medications were self-funded (out-of-pocket), as they are not covered by the national health insurance system.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 years or older * Overweight (BMI 25.0-29.9 kg/m²) or obesity (BMI ≥30.0 kg/m²) * Considered at increased metabolic risk for MASLD (overweight/obesity plus ≥1 additional cardiometabolic risk factor) * Continuous treatment with subcutaneous semaglutide or tirzepatide for at least 12 weeks Exclusion Criteria: * Significant alcohol consumption (\>30 g/day for men; \>20 g/day for women) * Chronic liver disease of other etiology (viral hepatitis, autoimmune hepatitis, hemochromatosis, Wilson's disease) * Prior bariatric surgery * Initiation or dose modification of pioglitazone, SGLT-2 inhibitors, or high-dose vitamin E within 3 months before baseline * Concurrent use of known hepatotoxic agents (e.g., amiodarone, methotrexate) * Missing clinical, anthropometric, or laboratory data at baseline or follow-up

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Insulin resistance are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fatty liver disease Insulin Resistance metabolic dysfunction-associated steatotic liver disease Obesity obesity disorder Overweight visceral steatosis, congenital

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Insulin resistance Metabolic liver injury Obesity Overweight Steatosis of liver

Contacts and locations

Locations

  • Facility: Istanbul Medeniyet University, Göztepe Prof. Dr. Süleyman Yalçın City Hospital

    Istanbul, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.